NCT07581470 Intravenous Dexamethasone (0 vs 4 vs 8 mg) as an Adjunct to PENG Block for Postoperative Analgesia in Total Hip Arthroplasty
| NCT ID | NCT07581470 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Poznan University of Medical Sciences |
| Condition | Osteoarthritis, Hip |
| Study Type | INTERVENTIONAL |
| Enrollment | 198 participants |
| Start Date | 2026-05-08 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 198 participants in total. It began in 2026-05-08 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
his study will test whether giving dexamethasone through a vein can improve pain control after total hip replacement surgery. Dexamethasone is commonly used to reduce nausea and may also help with pain, but it is not clear which dose works best. Patients will be randomly assigned to receive either no dexamethasone, 4 mg, or 8 mg, in addition to standard anesthesia and a nerve block (PENG block). The main goal is to see how long patients go without needing additional pain medication after surgery. The study will also look at pain levels, use of opioid painkillers, nausea and vomiting, blood sugar levels, and possible side effects.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Scheduled for elective total hip arthroplasty (THA) * Planned use of regional anesthesia including PENG block * American Society of Anesthesiologists (ASA) physical status I-III * Ability to understand the study procedures and provide written informed consent * Ability to assess pain using the Numeric Rating Scale (NRS) Exclusion Criteria: * Known hypersensitivity to dexamethasone or any component of the study medication * Chronic corticosteroid therapy or use of systemic steroids within 14 days prior to surgery * Active systemic infection or sepsis * Significant immunosuppression (e.g., chemotherapy, biological therapy) * Pregnancy or breastfeeding * Severe cognitive impairment or inability to reliably assess pain * Uncontrolled diabetes mellitus (e.g., HbA1c \> 8.5% or baseline blood glucose \> 200 mg/dL)
Contact & Investigator
Justyna Marszałek-Buko, MD
PRINCIPAL INVESTIGATOR
Poznan University of Medical Sciences
Frequently Asked Questions
Who can join the NCT07581470 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Osteoarthritis, Hip. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07581470 currently recruiting?
Yes, NCT07581470 is actively recruiting participants. Contact the research team at mreysner@ump.edu.pl for enrollment information.
Where is the NCT07581470 trial being conducted?
This trial is being conducted at Poznan, Poland.
Who is sponsoring the NCT07581470 clinical trial?
NCT07581470 is sponsored by Poznan University of Medical Sciences. The principal investigator is Justyna Marszałek-Buko, MD at Poznan University of Medical Sciences. The trial plans to enroll 198 participants.